FY2027 Earnings Forecast for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Investment analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of PolyPid in a report issued on Monday, June 2nd. HC Wainwright analyst B. Folkes expects that the company will post earnings per share of ($0.59) for the year. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s FY2028 earnings at $0.00 EPS and FY2029 earnings at $1.34 EPS.

PolyPid Stock Performance

NASDAQ PYPD opened at $3.14 on Tuesday. The firm has a 50-day moving average price of $2.71 and a two-hundred day moving average price of $2.93. PolyPid has a 12-month low of $2.30 and a 12-month high of $4.49. The company has a market capitalization of $32.00 million, a P/E ratio of -0.63 and a beta of 1.25. The company has a quick ratio of 1.00, a current ratio of 1.31 and a debt-to-equity ratio of 0.08.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.10.

Institutional Investors Weigh In On PolyPid

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rosalind Advisors Inc. grew its position in PolyPid by 49.9% during the fourth quarter. Rosalind Advisors Inc. now owns 1,018,021 shares of the company’s stock worth $3,095,000 after buying an additional 338,853 shares in the last quarter. J. Goldman & Co LP acquired a new position in PolyPid in the 4th quarter valued at $391,000. Finally, AIGH Capital Management LLC lifted its position in shares of PolyPid by 21.8% during the 4th quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock valued at $2,509,000 after acquiring an additional 148,199 shares during the period. 26.47% of the stock is currently owned by institutional investors and hedge funds.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.